Product Description
BTH1704 (BTH) is a humanized monoclonal antibody (MAb) targeting aberrantly glycosylated MUC1. (Sourced from: https://ascopubs.org/doi/abs/10.1200/jco.2015.33.3_suppl.tps493)
Mechanisms of Action: IgG1 Analogue
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: University of Illinois at Chicago
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Pancreatic Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| PM-01 | P1 |
Terminated |
Pancreatic Cancer |
2015-04-01 |
2021-04-03 |
Primary Endpoints|Treatments |
Recent News Events
Date |
Type |
Title |
|---|